February 24, 2026
Momoko Ishii, Mark Zervas
S elective S erotonin R euptake I nhibitors (SSRIs) and two psychedelics, Psilocybin (4-phosphoryloxy-N,N-dimethyltryptamine), and MDMA (3,4-Methylenedioxymethamphetamine) act on serotonergic-related neural circuits and function as serotonin modulators. All three molecules are either currently used or proposed as novel therapeutic modalities to treat P ost- T raumatic S tress D isorder (PTSD)....
Translation The University of Toledo Journal of Medical Sciences
February 17, 2026
Amy Hooper, Evelyn K. Lambe
MDMA-assisted psychotherapy has emerged as a promising treatment for post-traumatic stress disorder (PTSD), particularly in individuals unresponsive to conventional interventions such as SSRIs and trauma-focused cognitive behavioral therapy. As recent clinical trials report durable symptom remission, ongoing debate surrounds the mechanisms underlying its therapeutic effects. This review...
International Journal For Multidisciplinary Research
February 15, 2026
R Sruthi, A Seethalakshmi
Sleep paralysis is a distressing parasomnia marked by temporary immobility during sleep–wake transitions, often accompanied by intense fear and hallucinatory experiences. While traditionally explained through neurophysiological mechanisms, this contemporary review highlights the significant role of psychological factors in shaping both the onset and experience of sleep paralysis episodes....
Eurasian Journal of Current Research in Psychology and Pedagogy
February 13, 2026
G. K. Slanbekova
Post-traumatic stress disorder (PTSD) represents one of the most debilitating psychiatric conditions. Posttraumatic stress disorder is frequently accompanied by sleep disturbances, including insomnia and trauma-related nightmares, affecting up to 90% of individuals with this condition. This literature review examines the bidirectional relationship between sleep disturbances and PTSD symptoms,...
Research Square
February 11, 2026
Jack Swain, Davis Carter, Leonardo Vando
Abstract Background: Post-traumatic stress disorder (PTSD) is a common mental health condition affecting approximately 3-6% of the U.S. adult population annually, and is characterized by intrusive symptoms, avoidance, negative cognitive and mood alterations, and hyperarousal following trauma exposure. Ketamine shows promise as a treatment for PTSD in preliminary trials, though real-world...
Scientific Reports
February 10, 2026
Michelle Olofsson, Kasim Acar, Otto Simonsson et al.
Recent research has highlighted the potential of 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for the treatment of post-traumatic stress disorder and other trauma-related psychiatric conditions. However, less is known about the effects of MDMA use on psychological well-being in populations with trauma histories outside of clinical contexts. In the present study, we assessed...
Journal of Occupational and Environmental Medicine
February 2, 2026
Vivian Wl Tsang, Tavneet Walia, Katherine Sattler et al.
1 citation
Firefighters are exposed to a disproportionately high number of traumatic incidents and, thus, display elevated rates of trauma-related mental health disorders, with the reported average PTSD prevalence being 7.3% in firefighters vs 1.3-3.5% in the general populationOftentimes, conventional treatments demonstrate limited efficacy. Ketamine-assisted therapy (KAT) has recently arisen with...
Journal of Affective Disorders
February 2, 2026
Alene Sze Jing Yong, Aimee Freeburn, Suzie Bratuskins et al.
Australia recently became the first country to reschedule methylenedioxymethamphetamine (MDMA) to permit authorized prescribing for post-traumatic stress disorder (PTSD) outside of clinical trials. This study explored the direct experience of Australian clinicians, researchers, and patients regarding the use of MDMA-assisted psychotherapy (MDMA-AP) for PTSD to inform guideline development....
Psychopharmacology
February 1, 2026
Nicole L Zabik, Allesandra Iadipaolo, Craig A Peters et al.
Prior work from our lab and others demonstrates that the endocannabinoid system is a promising avenue for improving fear memory deficits in posttraumatic stress disorder (PTSD). Specifically, 7.5 mg of delta-9-tetrahydrocannabinol (THC) decreases fear responding in healthy adults and increases prefrontal cortex activation during extinction learning and fear renewal in adults with PTSD. The...